TY - JOUR T1 - Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients JF - Anticancer Research JO - Anticancer Res SP - 7119 LP - 7125 DO - 10.21873/anticanres.14741 VL - 40 IS - 12 AU - GIANLUCA VANNI AU - GIOVANNI TAZZIOLI AU - MARCO PELLICCIARO AU - MARCO MATERAZZO AU - ORSARIA PAOLO AU - FRANCESCA CATTADORI AU - FRANCESCA COMBI AU - SIMONA PAPI AU - CHIARA ADRIANA PISTOLESE AU - MARIA COTESTA AU - FRANCESCA SANTORI AU - JONATHAN CASPI AU - AGOSTINO CHIARAVALLOTI AU - SAVERIO MUSCOLI AU - VITTORIO LOMBARDO AU - ANTONELLA GRASSO AU - LORENZA CAGGIATI AU - ROBERTA RASELLI AU - DANTE PALLI AU - VITTORIO ALTOMARE AU - ROLANDO MARIA D’ANGELILLO AU - LEONARDO PALOMBI AU - ORESTE CLAUDIO BUONOMO Y1 - 2020/12/01 UR - http://ar.iiarjournals.org/content/40/12/7119.abstract N2 - Background/Aim: Extraordinary restrictions aimed to limit Sars-CoV-2 spreading; they imposed a total reorganization of the health-system. Oncological treatments experienced a significant slowdown. The aim of our multicentric retrospective study was to evaluate screening suspension and surgical treatment delay during COVID-19 and the impact on breast cancer presentation. Patients and Methods: All patients who underwent breast surgery from March 11, 2020 to May 30, 2020 were evaluated and considered as the Lockdown group. These patients were compared with similar patients of the previous year, the Pre-Lockdown group. Results: A total of 432 patients were evaluated; n=223 and n=209 in the Lockdown and Pre-lockdown-groups, respectively. At univariate analysis, waiting times, lymph-nodes involvement and cancer grading, showed a statistically significant difference (p<0.05). Multivariate analysis identified waiting-time on list (OR=1.07) as a statistically significant predictive factor of lymph node involvement. Conclusion: Although we did not observe a clinically evident difference in breast cancer presentation, we reported an increase in lymph node involvement. ER -